Arvinas, Inc. filings document regulatory, clinical, financial, and governance disclosures for a biotechnology company built around PROTAC targeted protein degradation. Recent Form 8-K reports cover FDA approval of VEPPANU (vepdegestrant) for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer, clinical data for ARV-102 in Parkinson’s disease, preclinical data for ARV-806 as a KRAS G12D degrader, and patient-reported outcomes for vepdegestrant.
The company’s filings also record quarterly and annual financial results, corporate updates, executive and board leadership changes, and proxy matters. Its definitive proxy statement addresses board elections, executive compensation, equity awards, shareholder voting items, and other governance information for Arvinas as a Nasdaq-listed operating company.
Arvinas, Inc. (NASDAQ: ARVN) — Form 144 filed for proposed insider sale
The notice, dated 24 June 2025, discloses an intent to sell up to 5,927 shares of Arvinas common stock through broker Morgan Stanley Smith Barney LLC. At an aggregate market value of US$43,593 and with 72,991,390 shares outstanding, the sale represents roughly 0.008 % of the company’s equity float.
The securities were acquired the same day via the vesting of restricted stock units issued by Arvinas, with no cash consideration. The filer reports no other sales in the previous three months and signs the customary representation that no undisclosed material adverse information is known.
Form 144 is a notice only; it does not obligate execution of the transaction. Given the small size relative to total shares outstanding and the lack of additional material disclosures, the filing appears routine and is unlikely to have a meaningful impact on Arvinas’ capital structure, operations, or near-term share price dynamics.
Arvinas, Inc. (ARVN) – Form 4 insider transaction filed 06/18/2025
Chief Scientific Officer Angela M. Cacace disclosed the sale of 2,583 common shares on 06/17/2025 at $7.49 per share. The company executed this sale automatically to satisfy tax-withholding obligations arising from the vesting and settlement of 50% of restricted stock units (RSUs) granted on 06/17/2024.
Post-transaction, the executive retains 154,248 shares held directly. No new options, warrants, or other derivative securities were reported, and the filing does not reference a Rule 10b5-1 trading plan.
Because the sale was issuer-directed and linked to tax withholding rather than discretionary portfolio rebalancing, it carries limited signaling value regarding the executive’s outlook. The relatively small size (≈1.7% of her holdings) further supports a neutral interpretation for investors.